Becton, Dickinson and Company (BD) has broken ground on a $187.3m (€165m) manufacturing facility in Zaragoza, Spain.

Initially, the new facility will have 8,000m2 area and will produce drug delivery devices, mainly for biopharmaceutical companies which supply drugs in pre-fillable syringes like vaccines and other biologic drugs in the European market.

Later, the plant will add the additional capacity required to support major vaccination campaigns.

The company has also started recruitment for key positions that support the design and construction of the new plant, which is expected to be open in late 2023.

BD Zaragoza facility program director Thibault Naegelen said: “These roles will be on the front lines of building a sustainable, state-of-the-art and fully digital site incorporating the latest in intelligent and autonomous solutions.

“We look forward to building a team in Zaragoza that helps BD meet its mission of advancing the world of health by supplying our European customers with devices that enhance drug delivery.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The manufacturing facility is expected to have 30,000m2 area and employ up to 600 people by 2030.

BD Pharmaceutical Systems worldwide president Eric Borin said: “Pre-fillable drug systems are a known factor in helping health care providers effectively, reliably and consistently administer drug therapies.

“This groundbreaking marks an important milestone in our ability to extend manufacturing capacity for our customers as they continue to grow their vaccine and biologic drug pipelines.”

The company stated that the construction of new manufacturing facility is part of the $1.2bn, four-year investment plan which was announced last year.

This investment is to expand and upgrade the company’s manufacturing capacity and technology for pre-fillable syringes as well as advanced drug delivery systems as part of BD’s 2025 growth strategy.

Currently, BD has three other production plants in San Agustín de Guadalix, Fraga and Almaraz in Spain.

———————————————————————————————————————

The new facility will produce drug delivery devices such as pre-fillable syringes. Credit: Arek Socha from Pixabay.